Close Menu

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The growing use of circulating cell-free (cfDNA) necessitates accurate variant detection at less than 1% allele frequencies due to a low population of DNA of interest within total cfDNA. This level of detection is critical for a variety of cfDNA applications including detection of circulating tumor DNA (ctDNA), detection of graft-derived cfDNA (GcfDNA) within normal plasma as a marker of graft integrity after organ transplantation, and for noninvasive prenatal testing (NIPT) where fetal cfDNA is detected at low frequencies in maternal plasma. 

Sponsored by

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.